This study compared autopsy tissue samples to clinical MRI from glioblastoma (GBM) patients to assess the effects of tumor outside of T1-contrast enhancement and FLAIR hyperintensity on clinical characteristics and outcomes. Non-enhancing tumors were more frequent amongst patients who had a history of bevacizumab treatment and no history of Tumor Treating Fields treatment. Additionally, non-enhancing tumors were associated with shorter overall survival times. These results suggest that non-enhancing tumors have clinically significant correlates and may result in worse survival outcomes for GBM patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords